Childhood Hodgkin Lymphoma Cases and Controversies Eurasian Commonwealth Online Conference 5/25/05 Scott Howard, MD, MSc St. Jude Children’s Research Hospital.

Slides:



Advertisements
Similar presentations
HODGKIN LYMPHOMA IN CHILDREN
Advertisements

Yasir Rudha, MD; Amr Aref, MD; Paul Chuba, MD; Kevin O’Brien, MD
Hematopathology Lab December 12, Case 1 . Normal Peripheral Blood Smear.
An Intergroup Randomised Trial of Rituximab versus a Watch & Wait Approach in Patients with Advanced Stage, Asymptomatic, Non-bulky Follicular Lymphoma.
Hodgkin’s Disease (HD)
HAEMATOLOGY MODULE: LYMPHOMA Adult Medical-Surgical Nursing.
Hodgkin lymphoma Histologic subtypes: - Nodular sclerosing - Mixed cellularity - Lymphocyte predominance -Lymphocyte depleted new category: - Lymphocyte.
How I treat relapsed and refractory Hodgkin lymphoma blood Prepublished online January 24, 2011; dr.kaji 1392.
Clinical Management of Lymphoma 新光醫院 血液腫瘤科 溫 武 慶.
Activity Faculty Scott C. Howard, MD, MSc University of Tennessee College of Health Sciences Memphis, TN.
CASE PRESENTATION  History: This patient is an almost three-year-old girl who presented with a two week history of ataxia and opsomyoclonus (loss of coordination.
Hodgkin Disease Definition: neoplastic disorder with development of specific infiltrate containing pathologic Reed-Sternberg cells. It usually arises in.
Results of a Phase II Trial of Brentuximab Vedotin as First Line Salvage Therapy in Relapsed/Refractory HL Prior to AHCT Chen RW et al. Proc ASH 2014;Abstract.
Focusing on Hodgkin Disease
The patient is a 65 year old man with a history of hypertension and valvular heart disease who presented with spontaneous hemorrhage of the.
Non-Hodgkin’s lymphomas-definition and epidemiology
© Copyright 2003 Cardinal Health, Inc. or one of its subsidiaries. All rights reserved. PET in Breast Cancer Early detection of disease Precise Staging.
Update on 18 F-Fluorodeoxyglucose/Positron Emission Tomography and Positron Emission Tomography/ Computed Tomography Imaging of Squamous Head and Neck.
Treatment Planning Hodgkin Lymphoma.
GASTRIC LYMPHOMAS Aswad H. Al.Obeidy FICMS, FICMS GE&Hep Kirkuk General Hospital.
Edward Camacho Mina 1061 MD4 WINDSOR UNIVERSITY HODGKIN LYMPHOMA.
SYB Case 2 By: Amy. History 63 y/o female History of left breast infiltrating duct carcinoma s/p mastectomy in 1996 and chemotherapy ER negative, PR negative,
In the name of God Isfahan medical school Shahnaz Aram MD.
Hodgkin’s Lymphoma By: Tonya Weir and Paige Mathias Date: October 13, 2010.
L YMPHOMA FOR THE G ENERALIST Lee Berkowitz, MD. G OALS AND O BJECTIVES 1. Understand the importance of pathology and staging in the approach to management.
K30 Case Presentation David Andorsky August 26, 2008.
Optimizing Timing of Transplant in Hodgkin Lymphoma Ginna G. Laport, MD Associate Professor of Medicine Division of Blood & Marrow Transplantation Stanford.
Clinical Correlations The NYU Internal Medicine Blog A Daily Dose of Medicine
Lymphoma Rob Jones. Aim and learning outcomes Aim ◦ To revise the key points of lymphoma Learning outcomes ◦ Revise the basics of haemopoiesis ◦ Understand.
APPROACH TO LYMPHOID MALIGNANCIES. Patient Evaluation of ALL Careful history and PE CBC Chemistry studies Bone marrow biopsy Lumbar puncture.
Week 6 BGD: Discussion on Hodgkin’s Lymphoma (Etiology, Immunology, Clinical Features, Staging Evluation, Treatment) Presented to the Department of Medicine.
Staging evaluation for NHL Ann Arbor Staging system is applicable to both Hodgkin’s disease and NHL.
Hodgkin’s Lymphoma Hodgkin’s Lymphoma Disease in which malignant (cancer) cells form in the lymph system Type of cancer that develops in.
HODGKIN’S LYMPHOMA. Anemia,bleeding tendency. Hepatosplenomegaly.
Journal Club Dr. Eyad Al-Saeed Radiation Oncology 12 January, 2008.
Supraclavicular metastasis from urothelial bladder carcinoma: A case report S. Farmahan, T. Mirza, P. Ameerally Oral Maxillofacial Department, Northampton.
Asymptomatic lymphadenopathy Mediastinal mass Systemic symptoms Fever, Pruritus Other nonspecific symptoms and paraneoplastic syndromes Intra-abdominal.
Non-Hodgkin Lymphoma March 13, 2013 Suzanne R. Fanning, DO Greenville Health System.
Proton Therapy Patterns-of-Care and Early Outcomes for Hodgkin Lymphoma: Results from the Proton Collaborative Group Registry Bradford Hoppe MD, MPH William.
Case report Ovarian cancer Ami Fishman, M.D. Meir Hospital - Sapir Med Center Kfar-Saba, Israel Ovarian cancer Ami Fishman, M.D. Meir Hospital.
ABNORMAL WBC’S. A 19 yr old man consults a physician about a 2 cm neck Mass. The patient has no systemic symptoms at that time. The mass is resected and.
Lymphoma Most present as tumor Involving lymph nodes or other lymphoid organs such as the spleen. But extra nodal presentation may seen. Hodgkin’s Lymphoma.
Abstract ID:  #427 Case Report: A Challenging Case of Managing Relapsed & Refractory Hodgkin's Lymphoma Prashanth Hari Dass, Michael B. Jameson, and Elliot.
Non-Hodgkin’s Lymphoma
Rob Corbett NCCN Christchurch
CT and PET imaging in non-small cell lung cancer
Modern Radiation Therapy for Nodal Non-Hodgkin Lymphoma—Target Definition and Dose Guidelines From the International Lymphoma Radiation Oncology Group 
Intensity modulated radiation therapy for definitive treatment of paraortic relapse in patients with endometrial cancer  Shervin M. Shirvani, MD, Ann.
Jeffrey Bradley, MD  Journal of Thoracic Oncology 
PANEL DISCUSSION ON CHALLENGES IN DISEASE RESPONSE STATUS
Lymphadenopathy in Children
Fig. 10. MIP (A, C) and axial non contrast fused 18F-FDG PET/CT (B) in 20-year-old man with ALK positive anaplastic large cell lymphoma. A. Patient had.
Response to chemotherapy
Lymphoma Most present as tumor Involving lymph nodes or other lymphoid organs such as the spleen. But extra nodal presentation may seen. Hodgkin’s Lymphoma.
Fig FDG PET-CT and diagnostic contrast-enhanced chest CT in patient with angioimmunoblastic T-cell lymphoma. MIP image (A) demonstrates intense 18FDG.
by Michele Paessler, and John Choi
by Thomas S. Uldrick, and Richard F. Little
Intensity modulated radiation therapy for definitive treatment of paraortic relapse in patients with endometrial cancer  Shervin M. Shirvani, MD, Ann.
Mediastinal lymph node staging of non-small-cell lung cancer: A prospective comparison of computed tomography and positron emission tomography  Walter.
Positron Emission Tomography in Lung Cancer
Gordon LI et al. Proc ASH 2010;Abstract 415.
Intensive chemotherapy and radical resections for primary nonseminomatous mediastinal germ cell tumors  Garrett L Walsh, MD, Grant D Taylor, BS, Jonathan.
The impact of 18F-FDG PET-CT scanning for staging and management of Merkel cell carcinoma: Results from Westmead Hospital, Sydney, Australia  Rebecca.
FDG PET/CT in Staging and Response Assessment in Non-Hodgkin Lymphoma
Preliminary Report of Late Recurrences, at 5 Years or More, after Stereotactic Body Radiation Therapy for Non-small Cell Lung Cancer  Yukinori Matsuo,
Jeffrey Bradley, MD  Journal of Thoracic Oncology 
Using PET in Lymphoma Place your logo here.
Hodgkin’s lymphoma stage I/II Untreated, age 15-70
Lymphomas.
Bradford Hoppe MD, MPH William Hartsell, MD
Presentation transcript:

Childhood Hodgkin Lymphoma Cases and Controversies Eurasian Commonwealth Online Conference 5/25/05 Scott Howard, MD, MSc St. Jude Children’s Research Hospital

Relapsed HL Evaluation Above the diaphragm Chest radiograph, Computed tomography Below the diaphragm Computed tomography or ultrasonography Tumor activity (Functional imaging) Gallium scan 18 FDG Positron emission tomography (PET)

Relapsed HL Evaluation Bone marrow biopsies All patients Bone scanIf there is bone pain, elevated alkaline phosphatase, or other sites of extranodal disease

Relapsed HL Evaluation Lymph node biopsy or fine needle aspirate Relapse therapy should NEVER be started without histologic confirmation of relapse. Evaluation of suspected relapse is the ONLY time a fine needle aspirate should be used for diagnosis of lymphoma in children.

Relapsed Hodgkin Lymphoma Treatment Depends on initial treatment –Low-intensity (< 4 chemo cycles) –High-intensity (>4 cycles + RT) Depends on the timing of relapse –PD on therapy, early, late, very late Depends on the extent of relapse –Localized versus extensive Depends on the site of relapse –Nodal versus extranodal

Treatment of HL after First Relapse Standard salvage regimen Intensive salvage regimen

Relapsed Hodgkin Lymphoma Treatment Depends on initial treatment –Low-intensity (< 4 chemo cycles) –High-intensity (>4 cycles + RT) Depends on the timing of relapse –PD on therapy, early, late, very late Depends on the extent of relapse –Localized versus extensive Depends on the site of relapse –Nodal versus extranodal

Treatment of HL after First Relapse Standard salvage regimen –Similar to initial therapy for advanced stage disease –6-8 cycles of chemotherapy –Radiation therapy Gy Intensive salvage regimen –Intense cytoreduction –Very intense consolidation (with stem cell rescue) –Radiation therapy Gy

Pediatric Hodgkin Lymphoma Initial Treatment Regimens MOPP and derivatives –COPP, ChlVPP, CVPP, OPPA ABVD and derivatives –OEPA, DBVE, VBVP, VAMP Stanford V BEACOPP

Treatment of HL after First Relapse Standard salvage regimen –Similar to initial therapy for advanced stage disease –6-8 cycles of chemotherapy –Radiation therapy Gy Intensive salvage regimen –Intense cytoreduction –Very intense consolidation (with stem cell rescue) –Radiation therapy Gy

Relapsed Hodgkin Lymphoma Treatment Schema Induction (cytoreduction) Consolidation #1 –chemotherapy vs –high dose chemotherapy with autologous stem cell rescue Consolidation #2 –radiation therapy

Treatment Schema for Relapsed HL Cytoreduction (Chemotherapy) Consolidation 1 (Intense Chemotherapy) Consolidation 2 (RT) CR or nice PR No PD

Cytoreduction Regimens ICE: Ifosfamide, Carboplatin, Etoposide MIED: High-dose MTX, Ifosfamide, Etoposide, Dexamethasone MIME: Methylguazone, Ifosfamide, Methotrexate, Etoposide ESHAP/ASHAP: Etoposide/Adriamycin, Solumedrol, High-dose-AraC, Cisplatin IV: Ifosfamide/vinorelbine GV: Gemcitibine/vinorelbine

Relapsed Hodgkin Lymphoma Case Presentation Multiple relapses in a 16 year old who received incorrect initial treatment

Relapsed Hodgkin Lymphoma Case Presentation # YOHF diagnosed with stage IIA mixed cellularity HL in 8/99 Sites: bilateral cervical, paratracheal Treatment: –8/99-10/99 COPP/ABVD x 2 “cycles” –10/99 XRT 10 cGy in 2 fractions to bilateral neck –10/99-3/00 COPP/ABVD x 4 “cycles” –4/00 No evidence of disease

Relapsed Hodgkin Lymphoma Case Presentation # Treatment: –4/00 No evidence of disease –4/00-7/00 3 more “cycles” of COPP/ABVD Recurrence #1: 8/2000 New cervical LAD –8/00-10/00 3 “cycles” of COPP/ABVD –11/00 XRT 36 Gy in 20 fractions to mantle, bilateral neck –1/01-2/01 2 “cycles” of MOPP/ABVD –4/01 No evidence of disease

Relapsed Hodgkin Lymphoma Case Presentation # Recurrence #2: 7/01 New left supraclavicular and axillary LAD –8/01 MIED #1 (CR after cycle #1!) –9/01 MIED #2 –10/01 CYTOP –11/01 XRT 36 Gy to left supraclavicular and axillary area Off-therapy evaluation 12/01

Patient After 2 Relapses (date 9/11/01)

Patient Off Therapy Evaluation (date 12/14/01)

Patient Four months later (3/25/02)

Patient /25/02

Histoplasmosis vs. Relapse

Relapsed Hodgkin Lymphoma Case Presentation First relapse in a 13 year old who received VAMP/COP (2 cycles each) + RT 25.5 Gy as initial treatment

Relapsed Hodgkin Lymphoma Case Presentation # year old white male Left cervical lymphadenopathy –strep negative –monospot negative –s/p multiple courses of antibiotics no soaking night sweats ADHD, weight loss temporal correlation with Ritalin.

Relapsed Hodgkin Lymphoma Case Presentation #18012 PE: matted left posterior cervical lymph nodes; 9 cm X 10 cm. ESR 20 LDH 502 mediastinal fullness gallium uptake in left cervical region only bone marrow negative

Relapsed Hodgkin Lymphoma Case Presentation #18012 Stage IIA enrolled on HOD 99 2 cycles VAMP 2 cycles COP 2550 mantle irradiation

Relapsed Hodgkin Lymphoma Case Presentation # month off-therapy evaluation left cervical lymphadenopathy 1.2 x 1.5 cm on exam needle biopsy : Hodgkin disease restaging: localized recurrence, gallium negative

2/7/2002

Relapsed Hodgkin Lymphoma Case Presentation First relapse in a 21 year old who received VAMP/COE (2 cycles each) + RT 25.5 Gy as initial treatment

Relapsed Hodgkin Lymphoma Case Presentation # YOWF with Stage IIA nodular sclerosing HL (intermediate risk) diagnosed 5/17/02 Enrolled on Hod 99  4 cycles of VAMP/COE + modified mantle RT (25.5 Gy) Completed treatment 11/13/02 Relapse 1/8/04 in porta hepatis and para-aortic lymph nodes

Relapsed Hodgkin Lymphoma Case Presentation #19090 MIED x 2 cycles (1/19/04-1/24/04 and 2/4/04-2/9/04)  30% tumor shrinkage, PET negative Stem cell pheresis on 2/16/04 ICE x 2 cycles (2/25/04-3/2/04 and 3/19/04-3/24/04)  PR (tumor shrank to 50% of initial relapse volume)

19090 At relapse 11/6/03

Relapsed Hodgkin Lymphoma Case Presentation #19090 ICE #2 complicated by hospitalization for febrile neutropenia Incidental PET finding: persistent avidity at the spinous process of C7 Biopsied and found to be necrotic Hodgkin lymphoma (possibly present at diagnosis 18 months prior, when PET scans were not routinely done)

Relapsed Hodgkin Lymphoma Case Presentation Progressive disease during therapy in a 16 year old who received VAMP/COE (2 cycles each) as initial treatment

Relapsed HL Case # YOWF with nodular sclerosing Hodgkin lymphoma diagnosed 11/11/03 Lab: normal CBC, normal chemistry and coagulation profiles, ESR 56, CRP 0.8. Sites of disease: bilateral supraclavicular, bilateral anterior cervical, internal mammary, and bilateral paratracheal nodes, and upper mediastinum

BP #20374 Gallium and PET avid in the bilateral supraclavicular nodes, mediastinum, and bilateral paratracheal nodes Stage IIA, intermediate risk (because of > 3 sites of disease) Hodgkin lymphoma Started therapy 11/26/03

BP #20374 VAMP x 2 cycles, COE x 2 cycles Came for radiation planning – exam ok, CT ok Returned 2 weeks later to start RT Had palpable lymphadenopathy in the left supraclavicular area Biopsy confirmed progressive Hodgkin lymphoma

BP #20374 Restaging evaluation: PET-positive enlarged lymph nodes in the left supraclavicular area and mediastinum Treated with MIED x 1  febrile neutropenia, partial response of the neck node by exam MIED #2 in process